AI is in Every Pharma Strategy Deck
Beyond Reporting - Safety surveillance analytics for medical devices...
Maximising Patient Engagement in Clinical Trials
Long-acting Injectable Formulations
LYMPHOMA TREATMENT AT A CROSSROADS
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)
PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad PhD is a seasoned biopharmaceutical expert with years in vaccine RD and manufacturing His PhD research pioneered costeffective processes for pneumococcal conjugate vaccines holds scholarly publications international patents and serves on editorial boards Based in Seattle currently works on cGMPcompliant process development and production at Inventprise Inc
Articles
The Growing Role of Biocatalysis in Industrial Synthesis
Since the late th century chemical catalysis has been a cornerstone of organic synthesis and pharmaceutical manufacturing driving the development and mass production of key therapeutic molecules across multiple disease areas Despite its broad adoption and long history traditional organic synthesis techniques remain constrained by several unavoidable drawbacks
Research Insights
Evaluation Of Giardia Lamblia Thioredoxin Reductase As Drug Activating Enzyme And As Drug Target
Abstract The antioxidative enzyme thioredoxin reductase TrxR has been suggested to be a drug target in several pathogens including the protist parasite Giardia lamblia TrxR is also believed to catalyse the reduction of nitro drugs eg metronidazole and furazolidone a reaction required to render these compounds toxic to G lamblia and other microaerophile
Case Studies
Bioavailability of Methadone After Sleeve Gastrectomy: A Planned Observational Case Study
Abstract Although there are no absolute contraindications to bariatric surgery most bariatric surgeons consider that patients with ongoing illicit drug use should not undergo such procedures The lack of clear recommendations within this field makes morbidly obese patients on opioidreplacement therapy a subgroup at risk for treatment refusal There is little
Techno Trends
A Breakthrough Therapy Developed for Investigational Prenatal Treatment ER-004 a Rare Genetic Condition
ER a breakthrough therapy for the prenatal treatment of XLHED a lifethreatening rare genetic condition was developed by EspeRare
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Artificial Intelligence in Oncology
Nancy Kapila is a seasoned pharmaceutical consultant with over 5 years of varied experience and a Master’s in Pharmaceutics from Panjab University. She excels in drug mechanisms and interactions. Her career highlights include collaborating with numerous pharmaceutical companies and offering strategic insights and guidance. Nancy stands out for her dedication to keeping abreast of pharmaceutical advancements, regulatory changes, and emerging trends. She believes in continuous learning to navigate the industry’s complexities and provide innovative client solutions. Fascinated by the role of data analytics in decision-making, Nancy delves into data to uncover patterns and opportunities, offering evidence-based recommendations for process optimization, product development, and operational efficiency. Her career is driven by a relentless pursuit of knowledge, passion for data insights, and commitment to leading pharmaceutical companies towards success in a dynamic industry.
Evolution of eCTD from version 1 to 4
Gouspasha is a seasoned professional with 12 years of experience in the pharmaceutical industry, specializing in eCTD (Electronic Common Technical Document) publishing and submission. With a strong focus on regulatory compliance and efficient document management, Gouspasha ensures seamless and timely submissions. Dedicated to maintaining the highest standards of quality and accuracy, Gouspasha remains committed to staying current with evo0lving industry trends and regulatory requirements.
From Gene Editing to Network Medicine
Prof. Dr. Hemanth Kumar Manikyam is a researcher in natural products chemistry and systems pharmacology. He is widely known as the father of Intrinsic Network Pharmacology (INP), an integrative framework combining artificial intelligence, biological network analysis, and traditional medicinal knowledge to explore complex therapeutic mechanisms and next-generation precision medicine.
3D Printing Revolutionising Nanotechnology
Mansi Athalye is Assistant Professor in Department of Pharmaceutics at L. M. College of Pharmacy, India with approx. 10 years of teaching and research experience. She has published 12 papers in international and national journals and has presented 22 papers in various conferences as author and co-author with 1 Indian Patent granted in 2018.
Sagar Popat is research student pursuing M. Pharmacy in Pharmaceutics at L. M. College of Pharmacy. He has worked on the topic ‘Cataract of goat eye lens by Invitro and Ex-vivo method’. He has published 1 research article and has won 1st prize in oral presentation at national level conference.
Kinase Inhibitors as Antiviral Agents
Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.
Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.
press releasesRead more...
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Alvotech a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited a global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines today announced the submissi...
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Inc a global commercialstage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases today announced the commercial launch of IMCIVREE setmelanotide in Japan to treat patients living with acquired hypothalamic obesity HO...
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Scinai Immunotherapeutics Ltd a biopharmaceutical company operating a growing contract development and manufacturing organization CDMO alongside an immunologyfocused therapeutic development platform today announced that its wholly owned subsidiary Scinai Biopharma Services Ltd has entered into a def...
EventsRead more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...
Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada
Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation
